By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

As a result, Moderna's shares have suffered, falling more than 90% since their peak in 2021. Now let's consider where Moderna will be a few years from now. The company recently said it aims to ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

A view of the headquarters of vaccine maker Moderna on May 08, 2020 in Cambridge, Massachusetts. - Image: Maddie Meyer / Staff (Getty Images) Moderna and other vaccine maker stocks plummeted ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some larger ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...